Vest Financial LLC Buys 1,419 Shares of Thermo Fisher Scientific Inc. $TMO

Vest Financial LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,918 shares of the medical research company’s stock after acquiring an additional 1,419 shares during the quarter. Vest Financial LLC’s holdings in Thermo Fisher Scientific were worth $4,009,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. KTF Investments LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $527,000. Wealthfront Advisers LLC lifted its stake in shares of Thermo Fisher Scientific by 25.6% in the 4th quarter. Wealthfront Advisers LLC now owns 28,123 shares of the medical research company’s stock valued at $16,296,000 after purchasing an additional 5,738 shares during the last quarter. Torren Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $85,000. Rogco LP lifted its stake in shares of Thermo Fisher Scientific by 12.2% in the 4th quarter. Rogco LP now owns 1,188 shares of the medical research company’s stock valued at $688,000 after purchasing an additional 129 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $55,000. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,800 shares of company stock worth $2,963,544. 0.33% of the stock is owned by insiders.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Erste Group raised its FY2026 and FY2027 EPS forecasts for TMO (FY2026 to $24.86 and FY2027 to $27.20), which suggests analysts see stronger forward earnings power and could support the stock.
• Positive Sentiment: Thermo Fisher opened a flagship U.S. Bioprocess Design Center to help customers accelerate biologics scale-up — a growth-area investment that reinforces exposure to high-margin bioprocessing demand. Thermo Fisher Opens Bioprocess Design Center
• Positive Sentiment: Thermo Fisher agreed to sell its microbiology/IVD business to private equity firm Astorg for about $1.1B — the divestiture reduces exposure to lower-growth IVD markets and frees cash that can be redeployed to higher-growth areas (or used for buybacks/debt reduction). Thermo Fisher inks $1.1B deal
• Neutral Sentiment: Thermo Fisher scheduled an Investor Day for May 20, offering management a platform to update strategy and guidance — the event could move the stock if new targets or capital-allocation plans are disclosed. Investor Day Announcement
• Neutral Sentiment: An insider (COO Gianluca Pettiti) sold 400 shares under a pre-arranged 10b5-1 plan — a small, planned reduction (1.57% of his holding) that typically has limited signal value for investors. Insider Sale Filing
• Neutral Sentiment: Investor commentary (Baron Capital / Baron Health Care Fund letter coverage) and broader articles offer mixed views on long-term growth; these are background context rather than direct catalysts. Baron Health Care Fund Letter

Thermo Fisher Scientific Price Performance

TMO stock opened at $466.04 on Thursday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business has a 50 day simple moving average of $496.82 and a 200-day simple moving average of $548.19. The firm has a market capitalization of $173.19 billion, a PE ratio of 25.62, a price-to-earnings-growth ratio of 2.07 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.83 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. UBS Group restated a “neutral” rating and set a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Finally, TD Cowen lowered their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $623.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.